US Patent

US12201614 — Methods for treating heterotopic ossification

Method of Use · Assigned to Clementia Pharmaceuticals Inc · Expires 2037-06-08 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating heterotopic ossification using palovarotene dosing regimens for oral administration.

USPTO Abstract

The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

Drugs covered by this patent

Sohonos (PALOVAROTENE) · Ipsen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4031`	—	Sohonos
`U-4031`	—	Sohonos
`U-4031`	—	Sohonos
`U-4031`	—	Sohonos
`U-4031`	—	Sohonos

Patent Metadata

Patent number: US12201614
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Clementia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.